Phase 2 Cystic Fibrosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are over 18 years old and have been diagnosed with cystic fibrosis (CF)
- You have been taking one of these CF medications for at least 30 days before the start of the study: ivacaftor, elexacaftor/tezacaftor/ivacaftor, or vanzacaftor/tezacaftor/deutivacaftor
- You have been diagnosed with CF-related diabetes (CFRD) and still have blood sugar problems at least 6 months after starting one of the above CF medications, shown by at least one of the following: currently using insulin, a long-term blood sugar test (HbA1c) above 6.5%, a fasting blood sugar level above 126 mg/dl, or a blood sugar level above 200 mg/dl taken at any time or during a sugar-drink test
Who may not be able to join:
- You have previously had a lung or liver transplant
- You currently need extra oxygen to breathe
- Your Body Mass Index (BMI) is below 18 (considered underweight)
- You were hospitalised or received antibiotic drips for a CF lung flare-up in the past 30 days
- You have taken steroid tablets or regular anti-inflammatory pain medications (such as ibuprofen) in the past 30 days
- You have significant heart, kidney, nerve, mental health, hormonal, or cancer-related conditions that could interfere with taking part in the study (confirm with trial site)
- Your liver function blood test results are significantly above the normal range, or your bilirubin level is above 3 mg/dL
- You are currently taking medications that are known to interact with metformin (confirm with trial site)
- You have a Vitamin B12 deficiency
- You are currently pregnant or breastfeeding
- You are a woman of childbearing age and are unwilling or unable to use an approved form of contraception during the study
- You are taking certain medications that strongly affect how the body processes drugs (known as strong CYP inducers or moderate-to-strong CYP inhibitors) (confirm with trial site)
- The study doctor believes you have any serious condition or abnormal test result that could put you at risk or make the study unsuitable for you
- You are already taking part in another clinical trial that could affect this study's results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Matthias A Salathe, M.D., Professor
Phone: 9135886000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in BK channel gene expression
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.